Ola Myklebost
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 36
- Cancer-related molecular mechanisms research 15
- MicroRNA in disease regulation 13
- Oncology top 1%
- Cancer-related Molecular Pathways 15
- Pulmonary and Respiratory Medicine top 0.5%
- Sarcoma Diagnosis and Treatment 67
- Molecular Biology top 1%
- Genomics and Chromatin Dynamics 15
- RNA modifications and cancer 14
- Molecular Biology Techniques and Applications 12
- Co-authors
- Leonardo A. Meza‐ZepedaØystein FodstadSissel RogneAnne ForusStine H. KresseEivind HovigKeith K. StanleyJoachim Herz
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Nucleic Acids Research (1 paper)Journal of Biological Chemistry (1 paper)
- Partner nations
- NorwayNetherlandsUnited States
In The Last Decade
Ola Myklebost
172 papers receiving 8.9k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Cancer Research 2.6k
- Oncology 2.5k
- Pulmonary and Respiratory Medicine 2.8k
- Molecular Biology 4.9k
- Pathology and Forensic Medicine 1.0k
Countries citing papers authored by Ola Myklebost
This map shows the geographic impact of Ola Myklebost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ola Myklebost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ola Myklebost more than expected).
Fields of papers citing papers by Ola Myklebost
This network shows the impact of papers produced by Ola Myklebost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ola Myklebost. The network helps show where Ola Myklebost may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ola Myklebost, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 5 | |
| 3 | 2023 | 1 | |
| 4 | 2022 | 34 | |
| 5 | 2022 | 10 | |
| 6 | 2021 | 5 | |
| 7 | 2021 | 35 | |
| 8 | 2021 | 6 | |
| 9 | 2018 | 60 | |
| 10 | 2018 | 38 | |
| 11 | 2017 | 31 | |
| 12 | 2016 | 27 | |
| 13 | 2012 | 36 | |
| 14 | 2011 | 376 | |
| 15 | 2011 | 83 | |
| 16 | 2011 | 1 | |
| 17 | Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapybreakdown → | 2006 | 553 |
| 18 | 2006 | 79 | |
| 19 | 2004 | 9 | |
| 20 | 1994 | 166 |
About Ola Myklebost
Ola Myklebost is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Gastroenterology, having authored 175 papers that have together received 9.0k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (67 papers), Cancer Genomics and Diagnostics (36 papers), Cancer-related Molecular Pathways (15 papers), Genomics and Chromatin Dynamics (15 papers), Cancer-related molecular mechanisms research (15 papers), RNA modifications and cancer (14 papers), MicroRNA in disease regulation (13 papers) and Molecular Biology Techniques and Applications (12 papers). The work is most often cited by research in Cancer Research (2.6k citations), Oncology (2.5k citations) and Pulmonary and Respiratory Medicine (2.8k citations). Ola Myklebost has collaborated with scholars based in Norway, Netherlands and United States. Frequent co-authors include Leonardo A. Meza‐Zepeda, Øystein Fodstad, Sissel Rogne, Anne Forus, Stine H. Kresse, Eivind Hovig, Keith K. Stanley, Joachim Herz, Heinrich Gausepohlꝉ and Ute Hamann. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.